Citations 1
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT‐1/‐2 studies
Cartin‐Ceba, Rodrigo , Halank, Michael , Ghofrani, Hossein‐Ardeschir, Humbert, Marc , Mattson, John P., Fritsch, Arno, Krowka, Michael J. , Ghofrani, Hossein Ardeschir , Krowka, Michael, Ghofrani, Hossein Ardeschir
Pulmonary Circulation | March 22, 2018 | Volume: 8 | Issue: 2 | Pages: 1-4
In patients with portopulmonary hypertension (n = 13) included in the 12‐week randomized placebo‐controlled PATENT‐1 trial, riociguat was well tolerated and improved 6‐min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open‐label extension, PATENT‐2.